30 results on '"Weisel K"'
Search Results
2. POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS
3. Pomalidomide, bortezomib and dexamethasone after one prior line of therapy in bortezomib-pretreated multiple myeloma: a subanalysis of the OPTIMISMM phase 3 trial
4. Ixazomib maintenance therapy following autologous stem cell transplantation significantly prolongs progression-free survival in patients with newly diagnosed Multiple Myeloma: phase 3 TOURMALINE-MM3 trial
5. POMALIDOMIDE plus BORTEZOMIB plus LOW DOSE OF DEXAMETASONE AFTER A PRIOR TREATMENT LINE IN PATIENTS WITH MULTIPLE MYELOMA PRE-TREATED WITH LENALIDOMIDE: OPTIMISMM SUBANALYSIS
6. OPTIMISMM: PHASE 3 STUDY OF POMALIDOMIDE, BORTEZOMIB, AND LOW DOSE OF DEXAMENTASONE VS. BORTEZOMIB AND LOW DOSE OF DEXAMETHASONE IN PATIENTS EXPOSED TO LENALIDOMIDE AFTER FIRST COLLECTION OF MULTIPLE MYELOMA
7. Phase 3 ELOQUENT-2 study extended 5-y follow-up comparing elotuzumab plus lenalidomide/dexamethasone (ELd) with Ld to treat relapsed/refractory multiple myeloma
8. DARATUMUMAB-BASED COMBINATION REGIMENS IN ELDERLY (>= 75 YEARS) PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CASTOR AND POLLUX STUDIES
9. Management of infusion-related reactions (IRRs) in patients (pts) receiving daratumumab plus standard of care for the treatment of multiple myeloma (MM) in the phase 3 studies CASTOR and POLLUX
10. Efficacy by cytogenetic risk status for daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone in relapsed or refractory multiple myeloma
11. Carfilzomib--dexamethasone vs bortezomib--dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
12. MM-013 phase 2 multicenter study of pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment
13. ELOTUZUMAB plus LENALIDOMIDE/DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: ELOQUENT-2 POST-HOC ANALYSIS OF PFS AND TUMOR REGROWTH BY TIME FROM DIAGNOSIS AND PRIOR LINES OF THERAPY
14. Elotuzumab plus lenalidomide and dexamethasone (ELd) in relapsed/refractory multiple myeloma (RRMM): ELOQUENT-2 post-hoc analysis of progression-free survival (PFS), tumor regrowth by time from diagnosis and prior lines of therapy, and median duration of response (DOR)
15. MANAGEMENT OF ADVERSE EVENTS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE: A POOLED SAFETY ANALYSIS OF 3 CLINICAL TRIALS
16. STRATUS (TM)(MM 010): A Single Arm, Phase 3b Study Evaluating Safety and Efficacy of Pomalidomide (POM)+ Low Dose Dexamethasone (LoDEX) in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM)
17. Adverse Event (AE) Management With Pomalidomide (POM)+ Low-Dose Dexamethasone (LoDEX) in the STRATUS (TM) Trial: A Phase 3b Study Evaluating Safety and Efficacy in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM)
18. Outcomes of Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI) Treated With Pomalidomide (POM)+ Low-Dose Dexamethasone (LoDEX) in the Phase 3b STRATUS (TM) Trial (MM-010)
19. Survival Outcomes in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) in the MM 003 Trial: Impact of Stable Disease (SD) as a Response to Pomalidomide Plus Low-Dose Dexamethasone (POM+ LoDEX)
20. MANAGEMENT OF ADVERSE EVENTS IN THE STRATUS TRIAL, A PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
21. Health resource utilization with continuous lenalidomide treatment (TX) in elderly patients with newly diagnosed multiple myeloma (NDMM)
22. IMPACT OF ECOG PERFORMANCE STATUS ON OVERALL SURVIVAL AND HRQOL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS FROM THE MM-003 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (DEX) vs HIGH-DOSE DEX
23. CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
24. EFFICACY, SAFETY, AND QOL IN MM-003, A PHASE3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF POMALIDOMIDE (POM) plus LOW-DOSE DEXAMETHASONE (LODEX) VS HIGH-DOSE DEXAMETHASONE (HIDEX) IN RRMM
25. ADVERSE EVENTS AND MANAGEMENT IN MM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
26. Quality of Life Improvements for Pomalidomide+ Low-Dose Dexamethasone (POM+ LoDEX) in Relapsed and Refractory MM (RRMM): P-430
27. MM-003 Trial: POM+ Low-dose DEX Extends OS and PFS vs. High-dose DEX in Patients Double-refractory to LEN and BORT: P-242
28. IMPACT OF RENAL IMPAIRMENT ON THE EFFICACY AND SAFETY OF MELPHALAN-PREDNISONE-LENALIDOMIDE (LEN) INDUCTION FOLLOWED BY LEN MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: MM-015 POST-HOC ANALYSIS
29. ANALYSIS OF MM-003 PATIENTS WITH MODERATE RENAL IMPAIRMENT USING POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
30. Progression-Free Survival (PFS) and Overall Survival (OS) Advantages with Pomalidomide+ Low-Dose Dexamethasone: MM-003: P-189
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.